Rocket Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Rocket Pharmaceuticals, Inc. (RCKT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $20.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-02-27
- Rocket Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $20.60M, a 19.77% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $17.20M, a 719.05% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $2.10M, a 70.83% decline from fiscal 2021.
- Rocket Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $7.20M, a 85.28% decline from fiscal 2020.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $20.60M 10-K · filed 2025-02-27 | |
| 2023-12-31 | $17.20M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $2.10M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $7.20M 10-K · filed 2023-02-28 | -$7.20M 10-K · filed 2022-02-28 |
| 2020-12-31 | $48.90M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $3.90M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $46.60M 10-K · filed 2020-03-06 | $46.02M 10-K · filed 2019-03-08 |
| 2017-12-31 | $46.02M 10-K · filed 2019-03-08 | -$13.41M 10-K · filed 2018-03-07 |
| 2016-12-31 | $1.27M 10-K · filed 2019-03-08 | $17.31M 10-K · filed 2017-03-16 |
| 2015-12-31 | $6.31M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $2.64M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |